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Abstract
Background: The total ankle replacement versus ankle arthrodesis (TARVA) trial aims to determine which surgical
procedure confers the greatest improvement in pain-free function for patients with end-stage ankle osteoarthritis.
Both procedures are effective but there has not yet been a direct comparison to establish which is superior. This
article describes the statistical analysis plan for this trial as an update to the published protocol. It is written prior to
the end of patient follow-up, while the outcome of the trial is still unknown.
Design and methods: TARVA is a randomised, un-blinded, parallel group trial of total ankle replacement versus
ankle arthrodesis. The primary outcome is the Manchester-Oxford Foot Questionnaire walking/standing domain
score at 52 weeks post-surgery. Secondary outcomes include measures of pain, social interaction, physical function,
quality of life, and range of motion. We describe in detail the statistical aspects of TARVA: the outcome measures,
the sample size calculation, general analysis principles including treatment of missing data, the planned descriptive
statistics and statistical models, and planned subgroup and sensitivity analyses.
Discussion: The TARVA statistical analysis will provide comprehensive and precise information on the relative effectiveness
of the two treatments. The plan will be implemented in January 2020 when follow-up for the trial is completed.
Trial registration: ISRCTN registry number 60672307, ClinicalTrials.gov registration number NCT02128555.
Registered 1 May 2014. Recruitment started in January 2015 and ended in January 2019.
Keywords: Statistical analysis plan, Arthritis, Osteoarthritis, Surgery, Total ankle replacement, Arthrodesis,
Randomised controlled trial, Pain-free walking, MOXFQ
Background
End stage ankle osteoarthritis (OA) causes pain and
chronic disability [1, 2]. It has been estimated that at
least 29,000 patients with symptomatic ankle OA are re-
ferred to specialist foot and ankle surgeons each year in
the UK, and that around 3,000 will choose to undergo
surgery with the NHS [3]. The main surgical treatments
for end-stage ankle OA are total ankle replacement
(TAR) or ankle arthrodesis (fusion) [4]. Improvements
in pain-free function and quality of life have been re-
ported for both TAR and fusion, but there has never
been a prospective randomised trial directly comparing
the two treatments [5].
TARVA is a parallel-group, non-blinded randomised
controlled trial that will compare clinical outcomes and
cost-effectiveness of TAR versus ankle arthrodesis in pa-
tients with end-stage ankle Osteoarthritis (OA). Full de-
tails of the background to the trial, the interventions
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: p.muller@ucl.ac.uk
1Comprehensive Clinical Trials Unit, Institute of Clinical Trials and
Methodology, University College London, London, UK
Full list of author information is available at the end of the article
Muller et al. Trials          (2020) 21:197 
https://doi.org/10.1186/s13063-019-3973-4
under study and its design are in the published trial
protocol [6]. From March 2015 to January 2019, 303 pa-
tients were randomised to surgery at one of 17 surgical
centres participating in the trial in England, UK.
This article describes the statistical analysis plan for
the TARVA trial. Analyses will commence in February
2020 following completion of 52 weeks follow-up for the
last patient, data cleaning checks, and data lock. The
analysis of the primary outcome will be independently
programmed from the cleaned derived dataset by a stat-
istician who did not perform the main analysis, and in
parallel by the trial statistician.
Objectives
The primary objective of the TARVA trial is to compare
TAR versus arthrodesis for:
 Improvement in self-reported pain-free function
from pre-operative assessment (“pre-op”) to 52
weeks after surgery (“post-op”)
The secondary objectives are to compare TAR versus
arthrodesis for:
 Improvement in self-reported pain, social
interaction, physical function, quality of life (QoL),
and total ankle range of motion (ROM) from pre-op
to 52 weeks post-op
 Improvement in self-reported pain-free function,
pain, social interaction, physical function, and QoL
from pre-op to 26 weeks post-op
 Safety
Design and methods
Design
TARVA is a two-arm, prospective, multi-centre, parallel-
group, non-blinded randomised controlled trial.
Patient eligibility criteria
Inclusion criteria:
 Diagnosis of end-stage ankle OA
 Aged 50–85 years inclusive
 The surgeon believes the patient is suitable for both
TAR and arthrodesis (having considered deformity,
stability, bone quality, soft tissue envelope, and
neurovascular status)
 The patient can read and understand the patient
information sheet (PIS) and trial procedures
 The patient is willing and able to provide written
informed consent
Exclusion criteria:
 Previous ipsilateral talonavicular, subtalar, or
calcaneocuboid fusion or surgery planned within 1
year of index procedure
 More than four lower limb joints fused (including
contralateral limb, but excluding PIPJ fusions)
 Unable to have either an MRI or a CT scan (e.g.
severe claustrophobia or contraindication for both
types of scan)
 History of local bone joint infection
 Severe osteoporosis (T score < − 2.5) with recent
fracture (< 12 months)
 Any co-morbidity which, in the opinion of the
investigator, is severe enough to:
Interfere with the patient’s ability to complete
the study assessments
Present an unacceptable risk to the patient’s
safety
 The patient is participating in another clinical trial
that would materially impact on their participation
in this study
Patients with end-stage OA in both ankles had only one
ankle randomised and operated on as part of the TARVA
trial; the other ankle was treated with usual care.
Randomisation and blinding
The randomisation process was based on a minimisation
algorithm. The algorithm gave an overall 85% chance of
allocating the patient to the treatment arm which was
under-represented with respect to three stratifying vari-
ables: surgeon, presence of OA in subtalar joint, and
presence of OA in talonavicular joint (as determined by
pre-operative MRI scan [7]). The research nurse or dele-
gated individual logged on to the sealed envelope ran-
domisation service and provided patient information
(including on stratifying variables) and the surgical treat-
ment to be received was supplied immediately.
Patients were allocated in a 1:1 ratio to the TAR and
arthrodesis arms. It was not possible to blind patients, sur-
geons, radiologists, and clinical assessors for the following
reasons: surgeons know what procedure they are perform-
ing, radiologists and patients will be able to identify from
radiographs which procedure has taken place, and patients
who receive ankle arthrodesis and their assessors will in-
variably know their ankle is stiff (a known consequence of
arthrodesis surgery) whereas those undergoing TAR will
retain motion in the ankle. To protect against allocation
bias, the person recruiting the patient to the study was not
aware of the allocation to be assigned prior to contacting
the randomisation service.
Trial intervention
At randomisation patients were allocated to receive
either TAR or ankle arthrodesis.
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For TAR, the remaining damaged cartilage is removed
and the joints are resurfaced with metal implants and an
intervening polyethylene liner that is either fixed or
mobile to act as a gliding surface. All prostheses are CE-
marked.
For ankle arthrodesis, the remaining damaged cartilage
is removed from the ends of the bone and the two bones
are then held together in compression using screws or
plates until they join to become one (bone fusion), so
that there is no longer any movement at that joint.
Full details of these interventions can be located in the
trial protocol [6].
Outcomes
Primary outcome measure
The primary outcome measure is the absolute difference
between the two treatment arms in self-reported pain-
free function, as measured by the Manchester-Oxford
Foot Questionnaire (MOXFQ) walking/standing domain
score [8] at 52 weeks post-op. The 52-week score will be
used if it was taken in a window from 48 to 56 weeks
post-op.
The MOXFQ standing/walking domain score has been
found to be a valid and responsive measure to evaluate
all types of foot and ankle surgery [9, 10], and it has add-
itionally been shown to be more responsive for the out-
comes of foot and ankle surgery patients than generic
QoL measures such as the EuroQol five-dimension
quality-of-life instrument (EQ-5D) and the Short Form
(36) Health Survey (SF-36) [11].
Secondary outcome measures
The secondary outcome measures for the trial are the
absolute differences between the two treatment arms in
the:
 MOXFQ walking/standing domain score at 26 weeks
post-op
 Self-reported pain and self-reported social
interaction, as measured by the MOXFQ pain and
MOXFQ social interaction domain scores at 26
weeks and 52 weeks post-op
 Physical function, as measured by the Foot and
Ankle Ability Measure Activities of Daily Living
(FAAM-ADL) questionnaire at 26 weeks and 52
weeks post-op
 Physical function for patients involved in sport, as
measured by the FAAM-Sport score at 26 weeks and
52 weeks post-op
 QoL assessed by the validated EQ-5D (EQ-5D Index
and EQ-5D Visual Analogue Scale (VAS)) at 26
weeks and 52 weeks post-op
 Total ROM (degrees plantarflexion and dorsiflexion)
at 52 weeks post-op, assessed by goniometer
 Proportion of patients experiencing at least one
adverse event (AE)
 Proportion of patients experiencing at least one
serious adverse event (SAE)
 Proportion of patients with recorded complications
(including revision surgery and reoperations other
than revision)
Additional outcomes are also collected for a detailed
cost and cost-effectiveness analysis of TAR versus ankle
arthrodesis; however, this analysis will not be performed
by the TARVA statistical team so these outcomes are
not described here. Further details on the cost effective-
ness analysis can be found in the trial protocol [6].
Calculation of outcome scores
The Manchester-Oxford Foot Questionnaire (MOXFQ)
Responses to each MOXFQ questionnaire item consist
of a five-point Likert scale ranging from no limitation
(scoring 0) to maximum limitation (scoring 4). Items are
grouped into three domains: walking/standing (seven
items), pain (five items), and social interaction (four
items). Domain scores are computed by summing the
patient’s responses to each item within the domain and
converting to a 0–100 metric, where higher scores repre-
sent greater severity.
If a single item within any domain is unanswered it
will be imputed with the mean of the respondent’s an-
swers to the other items within that domain. If two or
more questions on any domain are unanswered the
overall score for that domain will not be calculated and
its value will be set to missing [12]. If the entire ques-
tionnaire has not been completed all MOXFQ domain
scores for that visit will be set to missing.
The Foot and Ankle Ability Measure–Activities of Daily
Living (FAAM-ADL)
Each of 21 items on the FAAM-ADL are scored from
4 (no difficulty) to 0 (difficulty) [13]. The overall FAAM-
ADL score is then calculated by summing the responses
to each item completed, dividing this by the maximum
score achievable based on the number of items com-
pleted (e.g. 84 if all 21 items are completed), and then
multiplying the resulting fraction by 100 to return a 0–
100 metric, where higher scores indicate a higher level
of physical function. If an answer for one item is missing
its value will be imputed as the mode of the other items;
if more than one item is missing the overall score will be
set to missing.
The FAAM-Sport score provides a complementary
specific assessment of ability to participate in sports
based on eight questionnaire items, each also scored
from 0 to 4. A 0–100 metric is then generated using the
same approach as for the FAAM-ADL; higher scores
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indicate a higher level of ability to participate in sports.
Missing items will be handled using the same approach
as for the FAAM-ADL.
EuroQol 5D quality-of-life instrument (EQ-5D)
The EQ-5D assesses current health state across five
dimensions—mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression—with five levels
(each scored 1–5, with higher scores indicating worse
health state). EQ-5D dimension scores will be converted
to index scores using UK population values [14]. EQ-5D
index scores range from − 1 (worse than death) and then
0 (worst health state) to 1 (best health state). The EQ-
5D additionally includes a visual analogue scale (EQ
VAS), which allows patients to record their overall
current health status on a scale ranging from 0 (worst
health state) to 100 (best health state).
If any dimension score is missing, the EQ-5D index
score will be set to missing. If the entirety of one com-
ponent of the questionnaire (dimension score or VAS)
has not been completed the associated component score
will be set to missing. If the entire questionnaire has not
been completed, both the EQ-5D index score and EQ-
5D VAS at that visit will be set to missing.
Sample size
The sample size calculation for the primary outcome
(change in MOXFQ walking/standing domain by 52 weeks
post-op) was performed using Stata/IC version 12.1 [15].
It was based on achieving 90% power to detect the min-
imal clinically important difference (MCID) in the primary
outcome at the 5% level of significance, accounting for ex-
pected loss to follow-up. The trial is multi-centre and the
outcome plausibly varies by surgeon, so the sample size
was adjusted to account for clustering; the intraclass cor-
relation coefficient (ICC) was estimated based on previous
studies, and the initially computed sample size was in-
flated by a factor f = 1 + (m − 1) ∗ ICC [16].
The sample size calculation was partly based on the
study by Dawson et al. [9] which defined the MCID in
the MOXFQ when evaluating outcomes following sur-
gery for hallux valgus. They defined it as the mean
change in MOXFQ of those patients who reported feel-
ing at least “slightly better”, and found it to be 16, 12,
and 24, respectively, for the standing/walking, pain, and
social interaction domains of the MOXFQ. For this trial
we determined it was important to detect a difference of
12 in the change from baseline in MOXFQ standing/
walking domain between the two treatment arms; a con-
servative choice given the threshold for a MCID in the
standing/walking domain found in the Dawson et al.
study was 16. The standard deviation of the walking/
standing domain of the MOXFQ was estimated as 27
[11], and loss to follow-up was estimated as 10% (attri-
tion in similar RCTs has been 5–7% [17]).
Based on these quantities, the required sample size
was estimated as 118 patients per arm. Assuming an
average cluster size (m) of 14 (patients per surgeon)
and an ICC of 0.03 (estimated from the median of ten
previous surgical studies reporting patient-reported
disease-specific measures 12 months post-surgery [18]),
an inflation factor of f = 1.39 was estimated, leading to
a final required sample size of 164 per arm or 328
patients total.
The assumptions of ICC = 0.03 and equal numbers of
patients per surgeon in the sample size calculation [19]
were reviewed by the trial statistician prior to the end of
recruitment using the available data. The review indi-
cated lower ICC and also some variability in numbers of
patients per surgeon compared to the original assump-
tions (ICC < 0.01; average cluster size = 15, standard
deviation = 9.6), resulting in increased power.
Analysis principles
Patient population to be included in analysis
The main analysis will be conducted on an intention-to-
treat (ITT) basis; all observed outcome data from pa-
tients according to their randomised surgical procedure
will be used, irrespective of type of surgery received or
whether surgery was performed. Sensitivity analysis (de-
scribed below) will assess the impact of missing outcome
data.
Additionally, if cross-over prior to surgery does occur,
a per-protocol (PP) analysis will be performed for the
primary outcome that only includes data from patients
who undergo surgery according to their randomised sur-
gical procedure. The FAAM-Sport questionnaire is only
completed by patients who indicate they are involved in
sports. Analysis of the FAAM-Sport domain will there-
fore always be based on the subgroup of patients who
indicate they are involved in sports at baseline, following
the above principles.
Significance levels of tests and confidence intervals
All statistical tests will use a two-sided p value of 0.05,
unless otherwise specified. There will be no formal ad-
justment of p values for any interim analyses performed.
Two-sided 95% confidence intervals will be presented
for all estimates.
Baseline comparability
Baseline characteristics will be summarised by rando-
mised treatment arm. Categorical variables will be sum-
marised by number and percentage in each category;
continuous variables will be summarised by mean and
standard deviation, or median and interquartile range, as
appropriate. No statistical tests of differences in baseline
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characteristics between groups will be done, as any
differences between treatment arms must be due to
chance rather than bias.
Adjustment for design factors
Since randomisation is stratified by surgeon and pres-
ence of OA in two adjacent joints (subtalar and talonavi-
cular), analyses of outcomes will involve adjustment for
these factors (as recommended in ICH E9, section 5.7
[20]) unless otherwise indicated. Treatment effects will
then be estimated conditional on surgeon and presence
of OA in the two adjacent joints.
Baseline MOXFQ walking/standing domain will also
be adjusted for in primary analyses where this is the out-
come. Similar adjustment will be made for all continu-
ous secondary outcome variables where a baseline
measurement is recorded.
Follow-up and losses to follow up: missing data
Missing baseline covariate data are not anticipated since
covariates must be recorded to allocate treatment.
We expect that up to 10% of patients will not provide
measurements at 52 weeks post-op. Numbers and per-
centages of missing data at each visit (baseline, weeks 26
and weeks 52) will be tabulated by treatment group for
the primary and secondary outcomes (Additional file 1:
Table S2).
All observed data will be included in the primary and
secondary analyses. Missing outcome data will be as-
sumed to be missing-at-random (MAR) conditional on
the observed values of all other variables included in the
analysis models, and so independent of the values of the
unobserved data itself. As the primary outcome is the
change from baseline, patients without baseline and at
least one outcome score will consequently not be in-
cluded in the analysis. Their inclusion, however, would
not add any information to the analysis [21].
The characteristics of patients missing 52-weeks
MOXFQ data will be evaluated and a sensitivity analysis
will be done to examine the impact of departures from
the MAR assumption (described below).
Statistical analyses
All analysis will be carried out using Stata version 15 (or
above). The results of the analyses will be reported fol-
lowing the principle of the ICH E3 guidelines on the
Structure and Content of Clinical Study Reports [22]
and CONSORT guidelines [23].
Recruitment and follow-up patterns
The number of patients screened for eligibility will be
presented. Reasons for non-admissions into the trial will
be reported in a tabular form (listed in the dummy ta-
bles in Additional file 1: Table S1).
The period of data collection, including the date of the
first patient’s first visit and date of the last patient’s last
visit will be described. Recruitment will be presented by
year and centre. The throughput of patients from those
screened, those randomised, and those assessed at each
visit and included in the analysis will be summarised in
a CONSORT flowchart [23]. The average time between
pre-op assessment and surgery in each treatment arm
will be reported. The number of patients who withdraw
and are unwilling to provide follow-up will be reported
by treatment arm, as will the number of missing base-
line, 26-week, and 52-week CRFs (Additional file 1:
Table S2). Other lower limb surgeries occurring within
12months post-op will be reported by treatment arm,
with information on the type of surgery and side of the
body operated on.
Baseline characteristics
Baseline characteristics will be summarised in a table by
treatment arm. The variables to be reported in the baseline
tables are listed in the dummy tables (Additional file 1:
Table S3).
Trial treatment
The number of patients undergoing their randomised
surgery will be reported by treatment group. Although
it is made explicit that patients cannot change surgical
treatment arm once it has been randomly allocated,
the clinician remains free to give alternative treatment
to that specified in the protocol if it is felt to be in the
best interest of the patient. Any cross-overs or other
treatment deviations, as well as the number of patients
who did not undergo surgery of any kind, will be spe-
cified along with reasons, as detailed in the protocol
deviation log.
Analysis methods
Primary analysis
A multilevel repeated measures linear regression model
will be used to estimate the difference between the treat-
ment groups in MOXFQ walking/standing domain score
at 52 and 26 weeks post-op. Baseline scores will be ad-
justed for, so the model will return identical treatment
effect estimates as a model for change from baseline to
26 or 52 weeks with the same baseline adjustment [24].
This analysis model will use all available visit data
(from 26 weeks and 52 weeks) to strengthen confidence
in the MAR assumption and give greater power to detect
differences at individual visits.
The model for the MOXFQ walking/standing domain
will include fixed effects for time (two categories, 26
weeks/52 weeks), treatment (two categories, TAR/ankle
arthrodesis), treatment by time interaction, baseline
MOXFQ walking/standing domain (continuous), and
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presence of OA in each of the two adjacent joints as de-
termined by a pre-operative MRI scan (OA1, two
categories, present/absent subtalar joint; OA2, two cat-
egories, present/absent talonavicular joint). A random
patient effect will be included to take account of cluster-
ing by patient. A random surgeon effect, and an add-
itional random surgeon by treatment coefficient, will
also be included in the model to take account of cluster-
ing by surgeon and variation in the treatment effect by
surgeon. This will be modelled with an unstructured co-
variance structure. The model will be fitted using re-
stricted maximum likelihood estimation (REML).
The model for yijk, the MOXFQ walking/standing do-
main value at follow-up (either 26 or 52 weeks), where i
indexes the visit time, j the individual, and k the sur-
geon, will hence be:
yijk ¼ β0jk þ β1k treatmentjk
 þ β2 timeijk
 
þβ3 timeijktreatmentjk
 
þβ4 baseline MOXFQjk
 
þ β5 OA1jk
 
þβ6 OA2jk
 
ð1Þ
Where,
β0jk ¼ β0 þ v0k þ u0jk þ εijk
β1k ¼ β1 þ u1k
And,
v0k∼N 0; σ2v
 
u0jk∼N 0; σ2u0
 
εijk∼N 0; σ2
 
u1k∼N 0; σ
2
u1
 
And,
treatmentjk ¼ 1 if treatment is TAR and
0 if treatment is ankle arthrodesis:
The primary outcome is the average difference between
treatment groups at 52 weeks, estimated as β1 + β3.
Heterogeneity of surgeon cluster sizes may lead to
model convergence problems. Although randomisation
is stratified by surgeon, if a large number of surgeons
only see a very few patients there may be insufficient
data to estimate the random surgeon by treatment coef-
ficient. If the primary analysis model fails to converge,
the model will be refitted after excluding the random
surgeon by treatment coefficient.
The model makes assumptions about random effects
distributions, correlation structure, and residuals, which
will all need investigation. If any assumptions are poorly
met then transformation of the change in MOXFQ walk-
ing domain score may be required.
Secondary analysis
Continuous secondary outcomes The treatment group
difference in 26-week MOXFQ walking/standing domain
score will be obtained from the primary analysis model
(1) as β1.
Each of the following continuous secondary outcome
measures will be analysed using a separate multilevel
repeated measures linear regression model:
 MOXFQ pain domain score
 MOXFQ social interaction domain score
 FAAM-ADL
 FAAM-Sport (for patients involved in sport)
 EQ-5D Index
 EQ-5D VAS
 ROM dorsiflexion
 ROM plantarflexion
Similar to the primary analysis model, each model will
include fixed effects for treatment, time, treatment by
time interaction, baseline value of the associated score,
and presence of OA in each of the two adjacent joints as
determined by a pre-operative MRI scan. A random
patient effect, a random surgeon effect, and a random
surgeon by treatment coefficient will also be included in
each of the models. If convergence problems are experi-
enced, the approach outlined for the primary outcome
will be followed.
Adverse events, serious adverse events, and
complications The following absolute differences in
proportions will be estimated using the treatment coeffi-
cient obtained from a binomial regression model with
the identity link function:
 Proportion of patients experiencing at least one AE
 Proportion of patients experiencing at least one SAE
 Proportion of patients with at least one recorded
complication (any complication)
 Proportion of patients requiring revision ankle
surgery
 Proportion of patients experiencing reoperation
other than revision
 Proportion of patients experiencing surgical site
infection
Relative risks will be obtained from a binomial regres-
sion model with the log link. If convergence is an issue a
Poisson regression model with the log link and robust
error estimates will alternatively be fitted to obtain rela-
tive risks.
Unadjusted treatment differences will initially be
obtained for each of the event outcomes. The models
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will then be extended to adjust for presence of OA in
each of the two adjacent joints (OA1, OA2). Due to po-
tential sparse data in these outcomes, the models will
not adjust for surgeon.
The distribution of the AEs and SAEs per patient will
also be presented descriptively, but no formal analysis
will be performed.
Additional analyses
Subgroup analyses
An exploratory subgroup analysis will be performed
to investigate whether there is any interaction be-
tween the effect of treatment and the presence of OA
in each of the two adjacent joints on the primary
outcome.
The fitted primary analysis model will be extended to
include the interactions between treatment and presence
of OA in each of the two adjacent joints. As the trial has
not been powered to detect this, the analysis will have
limited power and is exploratory. We would anticipate
that the outcomes in TAR patients at 52 weeks are better
than arthrodesis patients when there is osteoarthritis in
adjacent joints.
Further exploratory subgroup analyses will be under-
taken similarly to investigate whether there is any inter-
action between patient preference (TAR, arthrodesis, or
no preference) and the effect of the treatment to which
the subjects are subsequently allocated, and whether
there are any interactions between treatment and age,
sex, or significant mal-alignment pre-surgery (as mea-
sured on plain AP radiographs, i.e. tibiotalar angle).
The fitted primary analysis model will be extended to
include the interaction between treatment and the asso-
ciated variable for each test.
All subgroup analyses are hypothesis generating and
will not form the basis of conclusions drawn from the
trial.
Sensitivity analyses
The robustness of the results to assumptions made
about missing data in the primary outcome will be
assessed. The primary analysis is only valid if the dis-
tribution of the 52-week MOXFQ scores are not dif-
ferent between the responses which are observed and
those which are unobserved (conditional on all base-
line response and covariates, treatment, and 26-week
post-op response), i.e. if these data are missing at
random.
Firstly, characteristics of patients missing a 52-week
response will be investigated using logistic regression,
with an indicator for missing data modelled on baseline
covariates and the data items collected at 26 weeks
post-op. Results from the model will provide contextual
information regarding the missing data and, together
with qualitative information gathered from the site
teams, will be used to explore potential mechanisms for
missing data.
Secondly, if more than 10% of patients operated on
are missing 52-week MOXFQ scores (the attrition as-
sumed in the original sample size calculation), a sen-
sitivity analysis will be done to explore the impact of
the primary outcome data being missing not at ran-
dom (MNAR). A pattern mixture modelling approach
will be adopted for the analysis [25]. It will explore
how different the unobserved responses would have
to be from the observed responses for inferences from
the primary analysis to change; specifically, how ex-
treme the departure from MAR would have to be for
the p value to change from p < 0.05 to p ≥ 0.05 (or
p ≥ 0.05 to p < 0.05).
In brief, multiple imputation will be used to produce
and analyse datasets with 52-week MOXFQ imputed on
the assumption that it is missing randomly conditional
on the other recorded variables. The number of imput-
ation datasets created, n, will be chosen to give a power
reduction of < 1% compared to using n = 100 [26].
Then, the imputed 52-week MOXFQ scores will each
have a number Ø added to them, and the multiple im-
putation primary analysis model will be run (with esti-
mates combined using Rubin’s rules [27]). The value of
Ø which causes the p value for the 52-week treatment
effect estimate to cross the 0.05 boundary will be iden-
tified and reported. This number is interpretable as
how different MOXFQ would have to be from expected
amongst the patients who did not attend at 52 weeks
for the analysis conclusions to change. The possibility
that data are MNAR in one treatment group only will
also be explored: only imputations in the TAR group
will be edited (missing data for the arthrodesis group
remain imputed under MAR) and the Ø which causes
the 52-week treatment effect estimate to cross the 0.05
boundary will be identified. Subsequently, only imputa-
tions for the arthrodesis group will be modified as
described above. Alongside information on the charac-
teristics of the patients missing 52-week MOXFQ
scores, these analyses will be used to consider whether
missing outcome data may compromise conclusions
from the primary analysis.
Discussion
This update contains the pre-specified statistical
analysis plan for the TARVA trial, written to conform
with the Journal of the American Medical Association
Guidelines for the Content of Statistical Analysis
Plans in Clinical Trials [28]. By publishing the statis-
tical analysis plan we aim to increase the transparency
of the data analysis. The TARVA trial will provide
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comprehensive and precise information on the relative
effectiveness of TAR versus ankle arthrodesis.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3973-4.
Additional file 1. Dummy tables. This file contains dummy tables which
show the planned format and contents of the tables for the TARVA final
statistical report.
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Foot Questionnaire; MRI: Magnetic resonance imaging; OA: Osteoarthritis;
PIS: Patient information sheet; QoL: Quality of life; ROM: Range of motion;
SAE: Serious adverse event; TAR: Total ankle replacement; TARVA: Total Ankle
Replacement Versus Arthrodesis trial; T-score: A measurement of bone
density expressed in standard deviation units from that of a healthy young
adult; UCL CCTU: UCL Comprehensive Clinical Trials Unit; VAS: Visual
analogue scale
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